glp-1 for psoriasis agonists reduce severity and inflammation | Shashank Joshi posted on the topic GLP-1 Agonists and Psoriatic Disease

In both patient populations with pre-existing cardiovascular disease, DPP-4 inhibitors are recommended as one possible third-line therapy besides SGLT-2 inhibitors, thiazolidinediones, or insulin, when therapeutic goals are not met with the previous dual combination

However, most modern GLP-1 medications are administered once per week

This review provides a meticulous exploration of GLP-1, elucidating its origin, secretion, and the challenges associated with its clinical application due to its fragility in the presence of DPP-IV, resulting in a short half-life

This dose provides mild appetite suppression, improves blood sugar control, and reduces gastric emptying, but the effect is significantly less than that of standard therapeutic doses